Beta Bionics has received clearance from the U.S. Food and Drug Administration (FDA) for the Mint wearable insulin pump, a move that gives it its first product of this kind and enables it to enter a market dominated by Insulet. Beta Bionics intends to begin the device’s full launch in the United States during the first quarter of 2027.
The Mint device is worn for up to three days and contains a 200-unit insulin reservoir. Its design relies on a combination of disposable and reusable components. Beta Bionics said the pump is smaller than Insulet’s competing pump, without the source providing additional details about the device’s dimensions or how its components are reused.
Direct Competition in the Tubeless Pump Market
Leerink Partners analyst Mike Kratky described the FDA clearance as something that could help narrow the gap between Beta Bionics and Insulet, which dominates new-device starts in the wearable pump market. According to Kratky, Beta Bionics will be the second company to offer a tubeless wearable pump on the market.
The company plans to make Mint available exclusively through pharmacy channels and expects to produce at least 1.5 million disposable units during 2027. This means the importance of the clearance is not limited to approving a new device; it also extends to the distribution model and the expected supply volume when the commercial launch begins.
Compatibility with Glucose Monitoring Devices
Mint will be compatible with continuous glucose monitors from Abbott and Dexcom. This compatibility gives users the ability to continue relying on familiar monitoring systems, but the source did not clarify whether the device will work with all models from the two companies or what the limits of integration between the pump and the monitors will be.
Separately, Senseonics announced that it will integrate its implantable continuous glucose monitor, which can be worn for one year, with Beta Bionics’ existing iLet Bionic Pancreas insulin pump. The company did not confirm whether this collaboration will extend to Mint.
New Dosing Algorithm Still Under Review
Beta Bionics submitted a new dosing algorithm called 3D Intelligence to the FDA for 510(k) clearance, but the application had not received approval according to the available information. The algorithm includes three settings based on the user’s insulin needs: a setting that continues to use the algorithm currently available in the iLet device, an updated version that benefits from practical experience with the device, and a setting that provides a more gradual response when correcting high glucose levels.
Immediate Commercial Impact
Beta Bionics expects some prospective users’ decision to wait for Mint rather than use iLet to affect its financial results. Therefore, it lowered its 2026 revenue forecast by $10 million, to a range of $121 million to $126 million.
certi.news analysis: The actual change is Beta Bionics’ transition from having a tubed pump to competing directly in the wearable pump category, with a defined launch date and a clear distribution channel. Open questions concern the price, insurance coverage terms, and software integration details, in addition to whether the 3D Intelligence algorithm will receive separate clearance before launch. These factors may determine Mint’s practical impact on patients’ options more than the device clearance itself.